Special Issue "Idiopathic Pulmonary Fibrosis Research"
A special issue of Medicina (ISSN 1010-660X).
Deadline for manuscript submissions: closed (30 June 2019).
Idiopathic pulmonary fibrosis (IPF) is a spontaneously occurring, specific and progressive form of chronic fibrosing interstitial pneumonia associated with a poor prognosis: Despite the introduction of the newest antifibrotic drugs, Pirfenidone and Nintedanib, the median survival of patients with IPF still amounts to less than 5 years. Approximately 10-20% of patients have an acute exacerbation every year, which increases the burden of the disease; furthermore, IPF is associated with a higher risk of comorbidities such as lung cancer, pulmonary hypertension and venous thromboembolism.
Prevalence is highly variable worldwide and appears to be increasing, although it is still not clear whether this reflects an increased ability in recognition or a true increase in incidence. It is now emerging that IPF pathogenesis relies on cycles of injury and dysregulated repair, and a number of familial cases, associated genetic defects, and other risk factors have also been described; however, despite an improvement in the understanding of the pathobiological mechanisms involved in the disease, it still represents a scientific and clinical challenge.
When IPF is suspected, diagnosis is usually supported by a typical interstitial pneumonia pattern on high-resolution CT or thoracoscopic lung biopsy, while further data are needed to recommend the use of molecular approaches as adjuvants to diagnosis in clinical practice.
Given the relevance of IPF in the fields of respiratory medicine and research, the journal Medicina is launching this Special Issue.
We are pleased to invite you and your co-workers to submit your articles reporting on the topic. Reviews or original articles focusing on the biochemical and molecular aspects underlying the pathobiology of IPF, as well as articles providing an up-to-date overview of the use of circulating/tissue biomarkers in early diagnosis and management, are particularly welcome. We would also like to invite you to submit review articles dealing with epidemiological aspects, prevention strategies targeting newly discovered risk factors, and recent advances in therapeutics with special regards to individualized approaches, efficacy and safety profile of currently available therapies, real-world studies included. Finally, we kindly invite you to submit your work or review data concerning the treatment of acute exacerbations and prognosis after lung transplantation.
Prof. Dr. Marco Confalonieri
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Usual Interstitial pneumonia
- Idiopathic pulmonary fibrosis
- Epithelial cells
- Real-world IPF treatment
- Respiratory failure
- Cell cycle
- Lung regeneration
- Diagnostic algorithms
- Biological markers
- Epithelial mesenchymal transition
- Lung biopsy
- Acute exacerbations
- Lung transplantation